Business UpdateApr 27, 2026, 04:49 PM
AVIR HCV Phase 3 Results Mid-2026; $25M Buyback; 25% Workforce Cut
AI Summary
Atea Pharmaceuticals announced its 2026 Annual Meeting of Stockholders for June 18, 2026, with proposals including director elections and auditor ratification. The company provided a business update, highlighting the advancement of its HCV Phase 3 clinical trials with topline results expected mid-2026 and year-end 2026. Atea also expanded its pipeline with AT-587 for HEV, initiated a 25% workforce reduction for $15 million in savings, and completed a $25 million stock repurchase program.
Key Highlights
- Annual Meeting of Stockholders scheduled for June 18, 2026.
- Completed $25 million stock repurchase, retiring 7,673,792 shares.
- Implemented ~25% workforce reduction, projected to save $15 million through 2027.
- HCV Phase 3 C-BEYOND trial topline results expected mid-2026.
- HCV Phase 3 C-FORWARD trial results anticipated by year-end 2026.
- Phase 2 HCV trial showed 98% sustained virologic response at 12 weeks.
- Global net sales of HCV therapeutics approximated $2.5 billion in 2025.
- Initiating Phase 1 program for AT-587 (HEV) mid-year 2026.